Molecular Cages for Alpha Particle Radioimmunotherapy

用于α粒子放射免疫治疗的分子笼

• 批准号: 6485043
• 负责人: MICHAEL D DIENER
• 金额: $ 10万
• 依托单位: TDA RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-06-06 至 2003-09-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6485043
• 关键词: actinides; alpha radiation; carbon; chelating agents; chemical synthesis; drug design /synthesis /production; immunologic substance development /preparation; laboratory mouse; monoclonal antibody; neoplasm /cancer radioimmunotherapy; radionuclides

Radioimmunotherapy (RIT) is a promising therapy for cancer, wherein radionuclides are linked to monoclonal antibodies specific for antigens expressed solely on tumor cells. Once the mAb locates the tumor cell, the radionuclide decays and kills the cell. The compounds that have so far undergone clinical trials are based on beta-emitting radionuclides, because they can be reliably linked to the mAb. However, alpha radiation has significant advantages for distributed carcinomas, including short path length and much greater cytotoxicity The development of alpha-emitting radionuclides has been severely hampered by a lack of robust chelates for radionuclides with therapeutically desirable half- lives. This project aims to develop a new encapsulate with 100% containment, suitable for all actinide radionuclides. PROPOSED COMMERCIAL APPLICATIONS: This encapsulate will enable alpha particle RIT methods to be developed for the treatment of leukemias, lymphomas, micrometastates, lung cancer, and other cancers where tumors are smaller than a few cell diameters. The development of such a therapy has a potential market of approximately 300,000 Americans/yr.

放射免疫治疗(RIT)是一种很有前途的癌症治疗方法，它将放射性核素与仅针对肿瘤细胞上表达的抗原的单抗连接起来。一旦单抗找到肿瘤细胞，放射性核素就会衰变并杀死细胞。到目前为止，已经进行了临床试验的化合物是基于贝塔发射的放射性核素，因为它们可以可靠地与单抗联系在一起。然而，对于分布式癌症，α辐射具有显著的优势，包括较短的路径长度和更大的细胞毒性。由于缺乏具有治疗希望的半衰期的放射性核素的坚固的螯合物，α辐射放射性核素的发展受到严重阻碍。本项目旨在开发一种100%包裹性的新包裹体，适用于所有氡系放射性核素。拟议的商业应用：这种胶囊将使阿尔法粒子RIT方法能够被开发出来，用于治疗白血病、淋巴瘤、微转移、肺癌和其他肿瘤小于几个细胞直径的癌症。这种疗法的开发每年有大约30万美国人的潜在市场。